Morgan Stanley’s Benitec Biopharma BNTC Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $312K | Sell |
29,270
-29,542
| -50% | -$342K | ﹤0.01% | 5684 |
|
|
2025
Q4 | $792K | Buy |
58,812
+42,695
| +265% | +$590K | ﹤0.01% | 5300 |
|
|
2025
Q3 | $226K | Sell |
16,117
-18,205
| -53% | -$232K | ﹤0.01% | 5848 |
|
|
2025
Q2 | $402K | Buy |
34,322
+7,662
| +29% | +$107K | ﹤0.01% | 5561 |
|
|
2025
Q1 | $347K | Sell |
26,660
-15,707
| -37% | -$190K | ﹤0.01% | 5497 |
|
|
2024
Q4 | $535K | Buy |
42,367
+41,043
| +3,100% | +$443K | ﹤0.01% | 5391 |
|
|
2024
Q3 | $12.2K | Sell |
1,324
-4,276
| -76% | -$38.3K | ﹤0.01% | 6660 |
|
|
2024
Q2 | $39.1K | Sell |
5,600
-6,200
| -53% | -$45.7K | ﹤0.01% | 6245 |
|
|
2024
Q1 | $62K | Buy |
11,800
+1,600
| +16% | +$6.14K | ﹤0.01% | 6136 |
|
|
2023
Q4 | $32.9K | Buy |
+10,200
| New | +$34K | ﹤0.01% | 6495 |
|
|
2023
Q3 | – | Sell |
-2,271
| Closed | -$9.21K | – | 7622 |
|
|
2023
Q2 | $9.21K | Sell |
2,271
-405
| -15% | -$1.54K | ﹤0.01% | 6838 |
|
|
2023
Q1 | $9.55K | Sell |
2,676
-19,025
| -88% | -$77.5K | ﹤0.01% | 6898 |
|
|
2022
Q4 | $62.7K | Buy |
21,701
+17,231
| +385% | +$58.4K | ﹤0.01% | 6191 |
|
|
2022
Q3 | $28K | Buy |
4,470
+4,129
| +1,211% | +$52.5K | ﹤0.01% | 6647 |
|
|
2022
Q2 | $7K | Buy |
341
+335
| +5,583% | +$7.79K | ﹤0.01% | 7306 |
|
|
2022
Q1 | $0 | Buy |
+6
| New | +$249 | ﹤0.01% | 7966 |
|
|
2021
Q2 | – | Sell |
-4,984
| Closed | -$438K | – | 7745 |
|
|
2021
Q1 | $438K | Buy |
4,984
+4,216
| +549% | +$287K | ﹤0.01% | 5227 |
|
|
2020
Q4 | $39K | Sell |
768
-1,281
| -63% | -$63.7K | ﹤0.01% | 6227 |
|
|
2020
Q3 | $219K | Buy |
2,049
+323
| +19% | +$39K | ﹤0.01% | 5065 |
|
|
2020
Q2 | $232K | Buy |
1,726
+601
| +53% | +$81.2K | ﹤0.01% | 5005 |
|
|
2020
Q1 | $113K | Buy |
1,125
+507
| +82% | +$59.3K | ﹤0.01% | 5140 |
|
|
2019
Q4 | $80K | Buy |
618
+307
| +99% | +$46.2K | ﹤0.01% | 5720 |
|
|
2019
Q3 | $56K | Buy |
311
+35
| +13% | +$6.43K | ﹤0.01% | 5675 |
|
|
2019
Q2 | $53K | Buy |
276
+24
| +10% | +$9.73K | ﹤0.01% | 5577 |
|
|
2019
Q1 | $126K | Buy |
252
+4
| +2% | +$1.72K | ﹤0.01% | 5288 |
|
|
2018
Q4 | $95K | Buy |
248
+15
| +6% | +$8.29K | ﹤0.01% | 5577 |
|
|
2018
Q3 | $141K | Buy |
233
+34
| +17% | +$23.2K | ﹤0.01% | 5584 |
|
|
2018
Q2 | $101K | Buy |
199
+34
| +21% | +$23K | ﹤0.01% | 5740 |
|
|
2018
Q1 | $134K | Buy |
165
+84
| +104% | +$70.7K | ﹤0.01% | 5625 |
|
|
2017
Q4 | $61K | Buy |
+81
| New | +$56.6K | ﹤0.01% | 5771 |
|
|
2016
Q2 | – | Hold |
0
| – | – | – | 6511 |
|
|
2016
Q1 | – | Hold |
0
| – | – | – | 6571 |
|
Other funds holding BNTC
SCM
RCM
NCM
VCM
IAM
Morgan Stanley's BNTC Position: Q1 2026 in Review
Morgan Stanley reduced its Benitec Biopharma (BNTC) stake by 50% in Q1 2026, selling an estimated $342K and leaving 29,270 shares worth $312K. The position accounts for ﹤0.01% of the portfolio, ranked #5684.
Morgan Stanley first reported a position in BNTC in Q4 2017 and has held it in 30 quarters since. The position peaked at $792K in Q4 2025. 88 funds tracked by Wall St. Rank hold BNTC as of Q1 2026.
- Morgan Stanley held 29,270 shares of Benitec Biopharma worth $312K as of Q1 2026.
- Morgan Stanley sold 29,542 Benitec Biopharma shares in Q1 2026, an estimated $342K.
- Benitec Biopharma made up ﹤0.01% of Morgan Stanley's portfolio in Q1 2026, its #5684 holding.
- Morgan Stanley first reported a position in Benitec Biopharma in Q4 2017 and has held it in 30 quarters since.
- Morgan Stanley's Benitec Biopharma position peaked at $792K in Q4 2025.
- 88 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2026.
Based on Morgan Stanley's 13F filing for Q1 2026, filed 15 May 2026.